---
figid: PMC6968989__428_2019_2726_Fig2_HTML
figtitle: Genetic pathways effected by mutations in maxillofacial bone tumours
organisms:
- Homo sapiens
- Mus musculus
- Hippospongia communis
pmcid: PMC6968989
filename: 428_2019_2726_Fig2_HTML.jpg
figlink: pmc/articles/PMC6968989/figure/Fig2/
number: F2
caption: Genetic pathways effected by mutations in maxillofacial bone tumours. a Osteomas
  in context of Gardner syndrome harbour APC mutations. APC mutations disable ubiquitination
  of β-catenin by β-TrCP, resulting in absence of the active destruction complex and
  no proteasomal degradation of β-catenin. Consequently, β-catenin levels rise causing
  cell proliferation, growth and differentiation. b MDM2 gene amplification in low-grade
  osteosarcoma leads to increased proteasomal degradation of P53, as MDM2 enables
  ubiquitination of P53, resulting in evading apoptosis. c The GNAS gene encodes subunit
  of G protein (α) and is important in the GCPR signalling pathway. GNAS mutation
  in fibrous dysplasia leads to increased levels of CAMP, thereby activation of CREB
  causing increased expression FGF23, resulting in mineralisation defect. GNAS mutations
  can also cause elevated levels of AKT, leading to evading apoptosis. d FGFR1, TRPV4
  and KRAS gain-of-function mutations lead to an increase activation ERK1/2 and thus
  overactivation of the RAS/MAP kinase pathway in central giant cell granuloma or
  peripheral giant cell granuloma. NF1 loss-of-function mutations in context of neurofibromatosis
  type 1 result in loss of inhibition of RAS
papertitle: Molecular findings in maxillofacial bone tumours and its diagnostic value.
reftext: Arjen H.G. Cleven, et al. Virchows Arch. 2020;476(1):159-174.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8794355
figid_alias: PMC6968989__F2
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC6968989__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6968989__428_2019_2726_Fig2_HTML.html
  '@type': Dataset
  description: Genetic pathways effected by mutations in maxillofacial bone tumours.
    a Osteomas in context of Gardner syndrome harbour APC mutations. APC mutations
    disable ubiquitination of β-catenin by β-TrCP, resulting in absence of the active
    destruction complex and no proteasomal degradation of β-catenin. Consequently,
    β-catenin levels rise causing cell proliferation, growth and differentiation.
    b MDM2 gene amplification in low-grade osteosarcoma leads to increased proteasomal
    degradation of P53, as MDM2 enables ubiquitination of P53, resulting in evading
    apoptosis. c The GNAS gene encodes subunit of G protein (α) and is important in
    the GCPR signalling pathway. GNAS mutation in fibrous dysplasia leads to increased
    levels of CAMP, thereby activation of CREB causing increased expression FGF23,
    resulting in mineralisation defect. GNAS mutations can also cause elevated levels
    of AKT, leading to evading apoptosis. d FGFR1, TRPV4 and KRAS gain-of-function
    mutations lead to an increase activation ERK1/2 and thus overactivation of the
    RAS/MAP kinase pathway in central giant cell granuloma or peripheral giant cell
    granuloma. NF1 loss-of-function mutations in context of neurofibromatosis type
    1 result in loss of inhibition of RAS
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Apc
  - Mdm2
  - Xiap
  - Gnas
  - Trpv4
  - Fgfr1
  - Kras
  - Nf1
  - Gpbar1
  - ac
  - Mmut
  - Ctnnb1
  - ras
  - Hras
  - Rem1
  - Akt1
  - Braf
  - Braf-rs1
  - Map2k2
  - Map2k1
  - Trp53
  - Atp5f1a
  - Mom6
  - Mapk3
  - Ppp1r15b
  - Creb1
  - Fgf23
  - APC
  - PROC
  - MDM2
  - GNAS
  - GNAO1
  - GNAI1
  - GNAI2
  - GNAI3
  - GNAT1
  - GNAT2
  - GNAT3
  - GNAZ
  - GNAL
  - GNAQ
  - GNA11
  - GNA14
  - GNA15
  - GNA12
  - GNA13
  - TRPV4
  - FGFR1
  - KRAS
  - NRAS
  - NF1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - FZD4
  - NMUR1
  - LPAR3
  - LGR6
  - MRGPRX3
  - MRGPRX4
  - GPR151
  - OXER1
  - GPRC6A
  - MRGPRX1
  - VN1R17P
  - GPR166P
  - GRM1
  - GRM2
  - GRM3
  - GRM4
  - GRM5
  - GRM6
  - GRM7
  - GRM8
  - CASR
  - GABBR1
  - GABBR2
  - GPR156
  - GPR158
  - GPR179
  - GPRC5A
  - GPRC5B
  - GPRC5C
  - GPRC5D
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - MTG1
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - MMUT
  - ATP8A2
  - CTNNB1
  - HRAS
  - AKT1
  - AKT2
  - AKT3
  - BRAF
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - MAP2K2
  - MAP2K1
  - TP53
  - TP63
  - TP73
  - ATP5F1A
  - MAPK3
  - PPP1R15B
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - APRT
  - MFAP1
  - ATP
  - CAMP
  - AMP
  - Osteomas
  - Gardner syndrome
  - APC
  - osteosarcoma
  - Fibrous Dysplasia
  - apoplosis
---
